OSI initially gained FDA approval for patients with metastatic EGFR T790M-mutant NSCLC that had progressed on first- or second-generation EGFR TKIs and has subsequently achieved approval as a first-line treatment of EGFR-mutant lung cancer [6,13,14]. This evidence concerns the gene EGFR and lung cancer.